HK1212920A1 - 使用麥膠蛋白肽治療癌症的套件和方法 - Google Patents

使用麥膠蛋白肽治療癌症的套件和方法

Info

Publication number
HK1212920A1
HK1212920A1 HK16100994.8A HK16100994A HK1212920A1 HK 1212920 A1 HK1212920 A1 HK 1212920A1 HK 16100994 A HK16100994 A HK 16100994A HK 1212920 A1 HK1212920 A1 HK 1212920A1
Authority
HK
Hong Kong
Prior art keywords
kits
cancer
treatment
methods
gliadin peptides
Prior art date
Application number
HK16100994.8A
Other languages
English (en)
Inventor
Fred L Shaw
Original Assignee
Barmarsa Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barmarsa Res Llc filed Critical Barmarsa Res Llc
Publication of HK1212920A1 publication Critical patent/HK1212920A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16100994.8A 2013-03-07 2016-01-29 使用麥膠蛋白肽治療癌症的套件和方法 HK1212920A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361774285P 2013-03-07 2013-03-07
PCT/US2014/021660 WO2014138556A1 (en) 2013-03-07 2014-03-07 Kits and methods for the treatment of cancer using gliadin peptides

Publications (1)

Publication Number Publication Date
HK1212920A1 true HK1212920A1 (zh) 2016-06-24

Family

ID=50483486

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100994.8A HK1212920A1 (zh) 2013-03-07 2016-01-29 使用麥膠蛋白肽治療癌症的套件和方法

Country Status (15)

Country Link
US (2) US9254308B2 (zh)
EP (1) EP2964242B1 (zh)
JP (1) JP6352952B2 (zh)
KR (1) KR102230514B1 (zh)
CN (1) CN105120881A (zh)
AU (1) AU2014225496B2 (zh)
BR (1) BR112015021448B1 (zh)
CA (1) CA2903471C (zh)
DK (1) DK2964242T3 (zh)
HK (1) HK1212920A1 (zh)
IL (1) IL241230B (zh)
MX (1) MX370858B (zh)
NZ (1) NZ711682A (zh)
SG (1) SG11201506963UA (zh)
WO (1) WO2014138556A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312810B (zh) * 2017-07-11 2020-10-09 南开大学 酶催化苯丁酸氮芥-多肽水凝胶的制备及抗癌应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2729296B1 (fr) * 1995-01-12 1997-03-28 Europlanaire Compositions pharmaceutiques comprenant une superoxyde dismutase
WO2003053332A2 (en) 2001-08-20 2003-07-03 Myriad Genetics, Inc Composition and method for treating viral infection
JP2004099459A (ja) * 2002-09-05 2004-04-02 Asama Chemical Co Ltd 抗腫瘍剤
WO2005021757A1 (en) 2003-09-01 2005-03-10 Galapagos Genomics N.V. Polypeptides and polynucleotides for use as a medicament
US8957032B2 (en) * 2008-05-06 2015-02-17 Alba Therapeutics Corporation Inhibition of gliadin peptides
US20120089541A1 (en) * 2010-08-31 2012-04-12 Genentech, Inc. Biomarkers and methods of treatment
WO2014002108A1 (en) 2012-06-27 2014-01-03 Amrita Vishwa Vidyapeetham University A core-shell nanostructure on the basis of proteins with corresponding therapeutic agents

Also Published As

Publication number Publication date
US9254308B2 (en) 2016-02-09
US20140256647A1 (en) 2014-09-11
US20160143991A1 (en) 2016-05-26
JP6352952B2 (ja) 2018-07-04
DK2964242T3 (en) 2019-03-04
NZ711682A (en) 2021-07-30
CN105120881A (zh) 2015-12-02
US9669068B2 (en) 2017-06-06
IL241230A0 (en) 2015-11-30
WO2014138556A1 (en) 2014-09-12
AU2014225496A1 (en) 2015-09-24
EP2964242A1 (en) 2016-01-13
SG11201506963UA (en) 2015-10-29
CA2903471C (en) 2022-11-01
IL241230B (en) 2021-02-28
KR20150138230A (ko) 2015-12-09
EP2964242B1 (en) 2018-11-14
MX370858B (es) 2020-01-08
MX2015011833A (es) 2016-06-02
BR112015021448A2 (pt) 2017-10-10
AU2014225496B2 (en) 2018-03-15
KR102230514B1 (ko) 2021-03-19
CA2903471A1 (en) 2014-09-12
BR112015021448B1 (pt) 2022-04-19
JP2016529202A (ja) 2016-09-23

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
HK1212363A1 (zh) 用於皮膚復新的肽及其使用方法
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
HRP20190888T8 (hr) Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
IL244590A0 (en) Anti-epcam antibodies and methods of use
PT2986633T (pt) Métodos para a expressão de proteínas e peptídeos
PT3089749T (pt) Preparações combinadas para o tratamento de cancro
IL250507B (en) Anti-ck8 antibodies for use in cancer treatment
HK1223547A1 (zh) 癌症治療方法
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu
LT2984108T (lt) Anti-s100a7 antikūnai, skirti vėžio gydymui ir diagnozei
HK1212920A1 (zh) 使用麥膠蛋白肽治療癌症的套件和方法
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
GB201301640D0 (en) Methods and peptides